. However, up to now, no fibrinolytic agent is capable of activating the fibrinolysis system specifically at the pathologic clot. In contrast, important changes of the plasmatic coagulation parameters (prothrombin time, activated partial thromboplastin time, thrombin time, fibrinogen) occur. This can cause severe hemorrhagias (lethal cerebral bleeding). There is some evidence that bolus-given (less controllable) thrombolytics are associated with more bleeding complications than the first-generation thrombolytic urokinase that is usually infused over a longer period (9, 11) .
Thrombolytically treated patients are high-risk patients: serious bleeding complications can occur and, at present, there is no laboratory assay for important hemostasis parameters of patients receiving fibrinolytic treatment. Therefore, we developed a technique to diagnose the fibrinolysis state of such patients, using arginine sta- 
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Summary: There are no reliable data on plasmin or plasminogen activator (PA) activities in blood of patients receiving fibrinolytic treatment. This is due to continuing in vitro action of PA after blood withdrawal. These artefactual changes of PA or plasmin activities have been prevented by arginine stabilization of blood samples of myocardial infarction patients treated with plasminogen activators. Twelve patients with myocardial infarction were treated with reteplase 2 × 10,000,000 units in bolus application; one patient was treated with 100 mg t-PA in continuous infusion. Blood was immediately stabilized with EDTA and arginine. The plasma was analyzed with newly developed assays for plasmin and PA. Maximal plasmin activities in blood were obtained at 40 to 60 minutes reteplase treatment time (0.1-0.6 U/mL = approximately 0.05-0.3 µmol/L plasmin). The 50% clearance rate for plasmatic Pli was greater than 30 minutes. The plasmatic reteplase concentration peaked at approximately 2000 U/mL after the first bolus infusion and at approximately 1500-3500 U/mL after the second bolus infusion. Reteplase was cleared to 50% within less than 30 minutes, also with great inter-individual variation. Arginine stabilization of blood allows reliable determinations of activities of plasmin and PA in blood of patients under fibrinolytic treatment: substantial plasmin activities occur in patients treated by reteplase. Therapeutic thrombolysis might be improved, imitating the physiologic cellular thrombolysis; i.e., polymorphonuclear phagocytes (PMN) that can be activated by singlet oxygen ( 1 O 2 ). PMN might be superior to PA in selective lysis of pathologic thrombi. Key Words: Plasmin-Plasminogen activator-Thrombolysis-Laboratory medicine.
bilization of blood (12, 13) . Here we present for the first time reliable measurement of plasmin and PA activities in fibrinolytic patients that allows control of treatment.
MATERIALS AND METHODS
Twelve patients with myocardial infarction were treated with reteplase, one patient with t-PA. The study was approved by the local ethical committee, and the patients gave informed consent to fibrinolytic analysis. No patient showed serious bleeding complications. The treatment regime was 2 IV boli of 10,000,000 units reteplase (RP) at a time lag of 15 minutes. Blood was sampled into 2.6 ml EDTA (1.6 mg/mL) monovettes (Sarstedt) at 0 minutes (before RP), 2 minutes, 17 minutes, 32 minutes, 62 minutes, and 92 minutes RP treatment time, if the clinical condition of the patient allowed blood sampling. The t-PA treatment consisted of the administration of a 10-mg IV bolus, followed by a continuous infusion of 90 mg t-PA; 60 mg over 30 minutes and 30 mg over 60 minutes. Blood was sampled at 0 minutes (before t-PA), at 15 minutes, 60 minutes, 90 minutes, 120 minutes, and 150 minutes t-PA treatment time.
After blood withdrawal, the 2.6-mL EDTA-blood was immediately given into a tube prefilled with 1.3 mL 1.5 M arginine, pH 8.7. The stabilized blood was transported into the central laboratory of the university hospital, centrifuged at 2500g, the arginine-stabilized plasma was aliquoted in 0.5-mL aliquots and frozen at -80°C. The test results for plasmin (Pli) and PA were hematocrit (HC)-dependently corrected, to obtain real plasma concentrations: correction factor of the assay results: (1.3 + (1-HC) * 2.6) / (2.6*(1-HC)).
Plasmatic PA and Pli-activity in patients receiving fibrinolytic treatment was determined as indicated in Table 1 . Because free plasmin is present in these plasmas, the PA-determination has to be corrected by the plasmin-baseline (Table 1) .
RESULTS

Plasmin Activity
Fig . 1A shows the plasmin activity in 12 patients with myocardial infarction treated with RP. Maximal Pli activities in plasma are obtained at 40 to 60 minutes treatment time: approximately 0.1 to 0.6 U/mL with great inter-individual vari-ation; 1 U/mL being the maximally PA inducible plasmin activity in normal plasma (approximately 0.53 µmol/L plasmin). The 50% clearance rate for plasmatic Pli is greater than 30 minutes. Fig. 1B demonstrates the plasmin activity under t-PA treatment. Maximal Pli-levels are reached at 60 to 90 minutes with approximately 0.06 U/mL plasmin in plasma. In this patient, the 50% clearance rate of Pli in blood is 60 minutes.
PA Activity
The plasmatic RP concentration peaked at approximately 2000 U/mL after the first bolus infusion and at approximately 1500 to 3500 U/mL after the second bolus infusion. Reteplase is cleared to 50% within less than 30 minutes also with great inter-individual variation ( Fig. 2A) . The plasmatic t-PA activity peaked at 15 to 60 minutes treatment time with approximately 1200 IU/mL plasma. At the end of t-PA infusion, the infused t-PA is cleared within 30 minutes from the circulation (Fig. 2B) .
DISCUSSION
This study presents for the first time reliable activities of plasmin and plasminogen activator in blood of patients receiving fibrinolytic treatment. Hitherto obtained results with unstabilized plasma are inaccurate because after blood withdrawal into usual citrate or EDTA tubes, plasminogen activators act on plasminogen, transforming it into plasmin. This results into artefactual changes of blood levels of plasmin. In addition, serine protease inhibitors of plasma also interact with the PA after blood withdrawal, resulting in falsely low PA activity levels. Thus, all available routine assays fail to diagnose the fibrinolytic state of these critical patients (14) (15) (16) (17) . Arginine inhibits serine proteases (18) . Therefore, arginine in final plasma concentrations greater than 500 mM prevents in vitro changes in plasmin or PA (12, 13) .
Active plasmin could be detected in the blood of all 12 RP-treated patients. The therapeutic concentration seems to be between 0.05 and 0.4 U/mL; however, great interindividual variation exists. Circulating active plasmin up to 0.06 U/mL could also be detected in the t-PA-treated patient. The apparent PA activities in blood also varied greatly interindividually, the range for RP was up to approximately 3500 U/mL, which corresponds well to immunoassay values for RP in clinical thrombolysis (19) . Urokinase-treated pa-tients have up to approximately 40 IU/mL u-PA in plasma that results in a free blood plasmin comparable to that with t-PA treatment (20, 21) . The t-PA-treated patient in this study had up to 1200 IU/mL t-PA independent of the infusion time. RP or t-PA were cleared within approximately 30 minutes from the circulation.
Thus, there is free plasmin in blood of patients conveniently treated with plasminogen activators. If plasmatic plasminogen is exhausted, serious bleeding complications might occur immediately and subsequently the patient might be at risk for re-thrombosis. FIG. 1. A. Plasmatic Pli activity in patients receiving fibrinolytic treatment by RP. The RP treatment in 12 patients consisted of 2 IV boli of 10,000,000 units RP at a time lag of 15 minutes. Blood was sampled into 2.6 mL EDTA (1.6 mg/mL) monovettes at 0 minutes (before RP), 2 minutes, 17 minutes, 32 minutes, 62 minutes, and 92 minutes RP treatment time. The withdrawn blood was immediately placed in a tube with 1.3 mL 1.5 M arginine, pH 8.7. The plasmin activity was determined as described in Methods; each patient has a symbol. B. Plasmatic Pli activity in patients receiving fibrinolytic treatment by t-PA. The t-PA treatment in one patient consisted of administration of a 10 mg IV bolus, followed by a continuous infusion of 90 mg t-PA, 60 mg over 30 minutes and 30 mg over 60 minutes. Blood was sampled at 0 minutes (before t-PA), at 15 minutes, 60 minutes, 90 minutes, 120 minutes, and 150 minutes t-PA treatment time as indicated in Fig. 2B . The plasmin activity was determined as described in Methods.
A B FIG. 2. A.
Plasmatic PA activity in patients receiving fibrinolytic treatment by RP. Twelve patients were treated by RP as described in Fig. 1a . The RP activity was determined as described in Methods; each patient has a symbol identical to that in Fig. 1A. B . Plasmatic PA activity in patients receiving fibrinolytic treatment by t-PA. A patient was treated by t-PA as described in Fig. 1B . The t-PA activity was determined as described in Methods.
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Therapeutic thrombolysis might be improved, imitating the physiologic cellular thrombolysis. The most important cells of cellular fibrinolysis are polymorphonuclear phagocytes (PMNs) (22) (23) (24) . PMNs or endothelium are activated by different stimuli, among them are fibrin or reactive oxygen species; activated PMN express the fibrin-receptor CD11b/CD18, activated endothelial cells ICAM-1, and E-selectin. Sialyl Lewis X-E-selectin binding and CD11b/18-ICAM-1 binding (25) cause the rolling of the PMN on the endothelium. 1 O 2 generation and CD11b/18 binding enhance each other and induce selective lysis of pathologic thrombi (26) (27) (28) .
For selective lysis of pathologic thrombi, a living cell such as an PMN is always superior to just a plasminogen activator molecule. Selective fibrinolysis is the ideal therapy form of atherothrombosis. Consequently, the plasmin level in the patient should be monitored and it should not exceed approximately 0.1-0.2 U/mL and the singlet-oxygen generating PMN system should be stimulated.
